TRISTEL plc – Preliminary Results

Preliminary Results for the Year Ended 30 June 2009

Tristel plc (TSTL), the specialist infection and contamination control company, announces its preliminary results for the year ended 30 June 2009. Tristel provides infection control products based on chlorine dioxide chemistry to the healthcare marketplace.

Financial Highlights

• Turnover up 14.9% to £6.847m (2008:  £5.961m)
• Profit before tax up 5.6% to £1.285m (2008:  £1.217m)
• Basic earnings per share 3.42p (2008:  4.17p) – 2008 benefited from a deferred tax adjustment
• Dividend per share for the full year up 9.7% to 1.7p (2007:  1.55p)

Operational Highlights

• Majority of Tristel products available to all NHS hospitals via NHS Logistics as a consequence of their widespread use
• Export sales increased by 53%
• Entry into the North American and Chinese markets
• Appointed UK distributor for AirinSpace’s complementary air hygiene products

Post year-end events

• Acquisition of the Medichem portfolio of disinfectants
• US licensing deal with The Clorox Company
• Launch of China based subsidiary

Paul Swinney, Chief Executive of Tristel plc, said:
“We have had another good year, achieving our fourth consecutive year of pre-tax profit growth since our flotation in 2005. Our business continues to grow, both at home and in overseas markets, and with our strategic initiatives to enter the Americas and Chinese markets we look to the future with confidence”